AMAGERBROKLINIKKEN ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  1.7% 1.4% 1.5% 1.3% 1.4%  
Credit score (0-100)  74 77 74 79 77  
Credit rating  A A A A A  
Credit limit (kDKK)  1.4 10.2 6.2 31.3 22.4  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  445 487 474 506 516  
EBITDA  445 487 474 506 516  
EBIT  424 466 453 485 495  
Pre-tax profit (PTP)  349.9 395.2 386.5 423.5 439.0  
Net earnings  270.5 305.5 298.6 327.5 339.6  
Pre-tax profit without non-rec. items  350 395 387 423 439  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  4,908 4,887 4,866 4,845 4,823  
Shareholders equity total  1,020 1,326 1,625 1,952 2,292  
Interest-bearing liabilities  3,746 3,484 3,219 2,936 2,666  
Balance sheet total (assets)  4,969 5,022 5,050 5,131 5,164  

Net Debt  3,686 3,349 3,035 2,650 2,326  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  445 487 474 506 516  
Gross profit growth  0.3% 9.5% -2.7% 6.8% 2.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  4,969 5,022 5,050 5,131 5,164  
Balance sheet change%  0.0% 1.1% 0.6% 1.6% 0.6%  
Added value  444.9 487.1 473.8 505.9 516.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -42 -42 -42 -42 -42  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  95.3% 95.7% 95.5% 95.8% 95.9%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  8.5% 9.3% 9.0% 9.5% 9.6%  
ROI %  8.7% 9.5% 9.1% 9.7% 9.8%  
ROE %  30.6% 26.0% 20.2% 18.3% 16.0%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  20.5% 26.4% 32.2% 38.0% 44.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  828.4% 687.4% 640.5% 523.9% 450.8%  
Gearing %  367.1% 262.8% 198.2% 150.4% 116.3%  
Net interest  0 0 0 0 0  
Financing costs %  1.9% 2.0% 2.0% 2.0% 2.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.2 0.4 0.5 0.8 1.0  
Current Ratio  0.2 0.4 0.5 0.8 1.0  
Cash and cash equivalent  60.8 135.7 184.7 286.0 340.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -285.2 -220.8 -170.9 -92.7 -5.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0